Salem Radio Network News Friday, December 3, 2021


Pfizer’s COVID-19 vaccine shows long-term efficacy in trial in adolescents

(Reuters) – Pfizer Inc said on Monday its COVID-19 vaccine showed 100% long-term efficacy in a late-stage study conducted among adolescents aged 12 to 15 years.

Data, measured seven days through over four months after the second dose, will support planned submissions for full regulatory approval of the vaccine in this age group in the U.S. and worldwide, the company said.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


Editorial Cartoons

View More »

Michael Ramirez
Thu, Nov 25, 2021